CIP
PCVX icon

Chartwell Investment Partners’s Vaxcyte PCVX Stock Holding History

Chartwell Investment Partners’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.62M Buy
14,146
+2,745
+24% +$247K 0.06% 310
2024
Q2 		$861K Sell
11,401
-1,865
-14% -$127K 0.03% 358
2024
Q1 		$906K Buy
13,266
+315
+2% +$21.8K 0.03% 372
2023
Q4 		$814K Buy
12,951
+4,558
+54% +$237K 0.03% 377
2023
Q3 		$428K Hold
8,393
– – 0.02% 398
2023
Q2 		$419K Buy
+8,393
New +$398K 0.02% 394

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Chartwell Investment Partners's PCVX Position: Q3 2024 in Review

Chartwell Investment Partners increased its Vaxcyte (PCVX) stake by 24% in Q3 2024, buying an estimated $247K and bringing the position to 14,146 shares worth $1.62M. The position accounts for 0.06% of the portfolio, ranked #310.

Chartwell Investment Partners first reported a position in PCVX in Q2 2023 and has held it in 6 quarters since. 328 funds tracked by Wall St. Rank hold PCVX as of Q3 2024.

  • Chartwell Investment Partners held 14,146 shares of Vaxcyte worth $1.62M as of Q3 2024.
  • Chartwell Investment Partners bought 2,745 Vaxcyte shares in Q3 2024, an estimated $247K.
  • Vaxcyte made up 0.06% of Chartwell Investment Partners's portfolio in Q3 2024, its #310 holding.
  • Chartwell Investment Partners first reported a position in Vaxcyte in Q2 2023 and has held it in 6 quarters since.
  • 328 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2024.

Based on Chartwell Investment Partners's 13F filing for Q3 2024, filed 4 Nov 2024.